Metastasis-related factors expressed in pT1 pN0 breast cancer: Assessment of recurrence risk

Journal of Surgical Oncology

Volumn 96, Issue 1, 2007, Pages 46-53

  Ogura, Shigeto ^a   Ohdaira, Takeshi ^a   Hozumi, Yasuo ^a   Omoto, Yawara ^a,b   Nagai, Hideo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Growth factor; Metastasis; Proteinase; pT1 pN0 breast cancer; Recurrence; VEGF

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CYCLINE; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE 14; PROTEIN P53; SCATTER FACTOR RECEPTOR; SIALYL LEWIS X ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34347351080     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20805     Document Type: Article

References (66)

1. Cummings SR, Lee JS, Lui LY, et al.: Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: A long-term prospective study. Cancer Epidemiol Biomarkers Prev 2005;14:1047-1051.
2. Kroman N, Jensen MB, Wohlfahrt J, et al.: Factors influencing the effect of age on prognosis in breast cancer: Population breast study. Br Med J 2000;320:474-478.
3. Yildirim E, Dalgic T, Berberoglu U: Prognostic significance of young age in breast cancer. J Surg Oncol 2000;74:267-272.
4. Lees AW, Jenkins HJ, May CL, et al.: Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989;13:143-151.
5. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
6. Ciatto S, Cecchini S, Grazzini G, et al.: Tumor size and prognosis of breast cancer with negative axillary nodes. Neoplasma 1990;37:179-184.
7. Lampe B, Hantschmann P, Dimpfl T: Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Arch Gynecol Obstet 1998;261:139-146.
8. Fisher B, Bauer M, Wickerham L, et al.: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update. Cancer 1983;52:1551-1557.
9. Dunne B, Going JJ: Scoring nuclear pleomorphism in breast cancer. Histopathology 2001;39:259-265.
10. Yang Q, Mori I, Sakurai T, et al.: Correlation between nuclear grade and biological prognostic variables in invasive breast cancer. Breast Cancer 2001;8:105-110.
11. Crowe JP, Gordon NH, Hubay CA, et al.: Estrogen receptor determination and long-term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1991;173:273-278.
12. UICC International Union Against Cancer: TNM classification of malignant tumours. New York: Wiley-Liss; 1997;
13. Vastag B: Consensus panel recommendation for treatment of early breast cancer. JAMA 2000;284:2707-2708.
14. Loprinzi CL, Thomas SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972-979.
15. Hebert-Croteau N, Brisson J, Latreille J, et al.: Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol 1999;17:1458-1464.
16. Saimura M, Fukutomi T, Tsuda H, et al.: Prognosis of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: Analysis of clinicopathological prognostic factors. J Surg Oncol 1995;71:101-105.
17. Fowble BL, Solin LJ, Schultz DJ, Goodman RL: Ten-year results of conservative surgery and irradiation for Stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1991;21:269-277.
18. Caceres E, Gamboa M: Treatment of breast cancer by radical surgery: A personal experience of 653 patients with minimal follow-up of 10 years. Semin Surg Oncol 1990;6:207-217.
19. Fracchia AA, Robinson D, Legaspi A, et al.: Survival in bilateral breast cancer. Cancer 1985;55:1414-1421.
20. Collett K, Maehle BO, Skjaerven R, Hartveit F: Lymph node-negative breast cancer: The prognostic role and time dependency of age, tumor diameter and mean nuclear area. Oncology 1994;51:323-328.
21. McGuire WL: Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 1988;6:1071-1072.
22. Nakopoulou L, Tsirmpa I, Alexandrou P, et al.: MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 2003;77:145-155.
23. Polette M, Gilles C, Nawrocki-Raby B, et al.: Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Birembaut P. Cancer Res 2005;65:7691-7698.
24. Deryugina EI, Ratnikov B, Monosov E, et al.: MT1-MMP initiates activation of pro-MMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001;263:209-223.
25. Toth M, Bernardo MM, Gervasi DC, et al.: Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 2000;275:41415-41423.
26. Maquoi E, Frankenne F, Baramova, et al.: Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem 2000;275:11368-11378.
27. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res 2001;21:2021-2028.
28. Nordqvist AC, Smurawa H, Mathiesen T: Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 2001;95:839-844.
29. Tang Y, Nakada MT, Kesavan P, et al.: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005;65:3193-3199.
30. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitor, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-168.
31. Tsutsui S, Yasuda K, Suzuki K, et al.: Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep 2005;14:425-431.
32. Nicolini A, Campani D, Miccoli P, et al.: Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study. Int J Biol Markers 2004;19:275-281.
33. Kinoshita J, Kitamura K, Kabashima A, et al.: Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001;66:159-164.
34. Skobe M, Hawighores T, Jackson DG, et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-198.
35. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer Oncologist 2000;5:137-144.
36. Coradini D, Boracchi P, Daidone MG, et al.: Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 2001;85:795-797.
37. Nagy J, Curry GW, Hillan KJ, et al.: Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 1996;5:15-21.
38. Zhou Z, Apte SS, Soininen R, et al.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Pro Natl Acad Sci 2000;97:4052-4057.
39. Horiguchi J, Iino Y, Takei H, et al.: Long-term prognostic value of PCNA labeling index in primary operable breast cancer. Oncol Rep 1998;5:641-644.
40. Aaltomaa S, Lipponen P, Syrijanen K: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res 1993;13:533-538.
41. Haerslev T, Jacobsen GK, Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 1996;37:101-113.
42. Yoshida R, Kimura N, Harada Y, Ohuchi N: The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001;18:513-520.
43. Heimann R, Lan F, McBridge R, Hellman S: Separating favorable from unfavorable prognostic marker in breast cancer: the role of E-cadherin. Cancer Res 2000;60:298-304.
44. Siitonen SM, Kononen JT, Helin HJ, et al.: Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996;105:394-402.
45. Oka H, Shiozaki H, Kobayashi K, et al.: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-1701.
46. Yamaguchi A, Ding K, Maehara M, et al.: Expression of nm23-H1 gene and sialyl Lewis X antigen in breast cancer. Oncology 1998;55:356-362.
47. Liang Y, Wu J, Stancel GM, Hyder SM: p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 2005;93:173-182.
48. Beenken SW, Grizzle WE, Crowe DR, et al.: Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53. Ann Surg 2001;233:630-638.
49. Takashima T, Onoda N, Ishikawa T, et al.: Proliferating cell nuclear antigen labeling index and p53 expression predict outcome for breast cancer patient with four or more lymph node metastases. Int J Mol Med 2001;8:159-163.
50. McLaughlin R, O'Hanlon D, McHale T, et al.: Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer. Ir J Med Sci 2001;70:11-13.
51. Gonzalez MA, Pinder SE, Wencyk PM, et al.: An immunohistochemical examination of the expression of E-cadherin, alpha-and beta/gamma-catenins, and alpha 2- and beta 1-integrins in invasive breast cancer. J Pathol 1999;187:523-529.
52. Dillon DA, D'Aquila T, Reynolds AB, et al.: The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. Am J Pathol 1998;152:75-82.
53. Nielson BS, Sehested M, Kjeldsen L, et al.: Expression of matrix metalloproteinase-9 in vascular pericytes in human breast cancer. Lab Invest 1997;7:345-355.
54. Talvensaari MA, Paakko P, Turpeenniemi HT: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-negative breast carcinoma. Cancer Res Treat 1999;58:287-293.
55. Gilles C, Bassuk JA, Pulyaeva H, et al.: SPARC/osteonectin induces matrix metalloproteinase2 activation in human breast cancer cell lines. Cancer Res 1998;58:5529-5536.
56. Sato H, Okada Y, Seiki M: Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost 1997;78:497-500.
57. Ueno H, Nakamura H, Inoue M, et al.: Expression and tissue localization of membrane-type 1, 2 and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-2060.
58. Visscher DW, Hoyhtya M, Ottosen SK, et al.: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994;59:339-344.
59. Narita T, Funahashi H, Satoh Y, et al.: Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 1993;71:3044-3053.
60. Valtola R, Salven P, Heikkila P, et al.: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-1390.
61. Gunningham SP, Currie MJ, Han C, et al.: VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol 2001;193:325-332.
62. Nagaoka H, Iino Y, Takei H, Morishita Y: Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998;13:449-454.
63. Rudolph P, Olsson H, Bonatz G, et al.: Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications. J Pathol 1999;187:207-216.
64. Bodey B, Groger AM, Luck JV, et al.: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene protein in human breast cancer cells: clinical and therapeutical significance. Anticancer Res 1997;17:1311-1318.
65. Stenmark AM, Stal O, Olsen K, Nordenskjold B: p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group. Br J Cancer 1995;72:715-719.
66. Pellikainen JM, Ropponen KM, Kataja VV, et al.: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-7628.